Phage Receptor-Binding Proteins for Targeted Silver Nanoparticle Delivery: Design and Evaluation.
- 1Military Medical Sciences Academy, Academy of Military Sciences, Tianjin 300050, China.
Abstract
Antimicrobial resistance has renewed interest in silver nanoparticles (AgNPs), but limited pathogen selectivity complicates their therapeutic use. Bacteriophage receptor-binding proteins (RBPs) recognize bacterial surface receptors and offer candidate targeting modules for AgNP delivery. However, evidence from intact-phage composites and non-silver carriers cannot establish the performance of isolated RBP-AgNP systems. In this review, we link RBP architecture and receptor recognition to ligand selection, orientation and multivalent display on AgNPs. We outline workflows for RBP discovery and receptor assignment, review conjugation strategies, and examine how Ag⁺ release and oxidative stress contribute to antibacterial activity. We propose a dual-endpoint framework to quantify nanoparticle enrichment near target bacteria and test for bactericidal gain using receptor-level controls, matched total silver doses and measurements of silver release. We discuss protein-corona masking, receptor variation and activity retention in complex infection settings, including biofilms, alongside manufacturing reproducibility. Translation further requires formulation-specific assessment of in vivo exposure, host tolerance, environmental fate and ecological risk. This framework defines the evidence needed to determine whether RBP-guided delivery improves antibacterial efficacy and safety.
Related
- Aptamer-Targeted PLGA Nanoparticles for Biofilm-Directed Intra-articular Antibiotic Delivery in Prosthetic Joint Infection
- A macrophage-targeted TIMD4 Peptide-Nanoparticle attenuates colitis symptoms and monocyte recruitment in a mouse model
- Programming Targeted Immune Cell Migration Using Orthogonal Chemokine-Receptor Pairs
- Single-vector AAV delivery of En-ISPmu1 and donor DNA for in vivo targeted genome integration
- Coronavirus nucleocapsid proteins differentially antagonize RIG-I-like receptor signaling to shape pathogenicity
BibTeX
@article{he2026phage,
title = {{Phage Receptor-Binding Proteins for Targeted Silver Nanoparticle Delivery: Design and Evaluation.}},
author = {Qing He and Xiaobo Yang and Zhigang Qiu},
journal = {Viruses},
year = {2026},
month = oct,
doi = {10.3390/v18101145},
url = {https://europepmc.org/article/MED/42944064},
note = {CC BY},
}
RIS
TY - JOUR
TI - Phage Receptor-Binding Proteins for Targeted Silver Nanoparticle Delivery: Design and Evaluation.
AU - Qing He
AU - Xiaobo Yang
AU - Zhigang Qiu
PY - 2026
DA - 2026/10/15
JO - Viruses
DO - 10.3390/v18101145
UR - https://europepmc.org/article/MED/42944064
AB - Antimicrobial resistance has renewed interest in silver nanoparticles (AgNPs), but limited pathogen selectivity complicates their therapeutic use. Bacteriophage receptor-binding proteins (RBPs) recognize bacterial surface receptors and offer candidate targeting modules for AgNP delivery. However, evidence from intact-phage composites and non-silver carriers cannot establish the performance of isolated RBP-AgNP systems. In this review, we link RBP architecture and receptor recognition to ligand selection, orientation and multivalent display on AgNPs. We outline workflows for RBP discovery and receptor assignment, review conjugation strategies, and examine how Ag⁺ release and oxidative stress contribute to antibacterial activity. We propose a dual-endpoint framework to quantify nanoparticle enrichment near target bacteria and test for bactericidal gain using receptor-level controls, matched total silver doses and measurements of silver release. We discuss protein-corona masking, receptor variation and activity retention in complex infection settings, including biofilms, alongside manufacturing reproducibility. Translation further requires formulation-specific assessment of in vivo exposure, host tolerance, environmental fate and ecological risk. This framework defines the evidence needed to determine whether RBP-guided delivery improves antibacterial efficacy and safety.
SN - 1999-4915
ER -